摘要
目的观察卡培他滨单药对晚期复发性卵巢癌患者的疗效和不良反应。方法 27例晚期复发性卵巢癌患者,给予卡培他滨2500 mg/m2,2次/d,连用14 d,休息7 d,每21天重复,直到疾病进展,最多6周期。结果部分缓解11例,稳定10例,疾病进展6例,总有效率40.7%,肿瘤控制率77.8%,中位肿瘤进展时间（m TTP）7.8个月。不良反应有：Ⅰ~Ⅱ度手足综合征5例,发生率18.5%,Ⅰ~Ⅱ度骨髓抑制6例,发生率22.2%,Ⅰ度腹泻2例,发生率为7.4%,Ⅰ度消化道反应2例,发生率为7.4%。结论卡培他滨单药治疗晚期复发性卵巢癌患者有较高疾病控制率,不良反应轻微,值得临床推广。
Objective To observe the curative effect and adverse reactions of capecitabine in monotherapy of advanced recurrent ovarian cancer. Methods A total of 27 patients with advanced recurrent ovarian cancer received capecitabine as 2500 mg/m2 by 2 times/d for 14 d, followed by 7 d of rest. The treatment repeated every 21 d until progression of disease, for 6 courses at most. Results There were 11 cases with partial remission, 10 cases with stable disease and 6 cases with progressive disease. The total effective rate was 40.7%, tumor control rate was 77.8%, and median time to tumor progression （mTTP） was 7.8 months. Adverse reactions included 5 cases withⅠ~Ⅱdegree of hand-foot syndrome, with occurrence rate as 18.5%, 6 cases withⅠ~Ⅱdegree of myelosuppression, with occurrence rate as 22.2%, 2 cases withⅠdegree of diarrhea, with occurrence rate as 7.4%, and 2 cases withⅠdegree of gastrointestinal reaction, with occurrence rate as 7.4%. Conclusion Implement of capecitabine in monotherapy of advanced recurrent ovarian cancer can provide high control group with mild adverse reactions, and it is worthy of clinical promotion.
出处
《中国现代药物应用》
2015年第11期63-64,共2页
Chinese Journal of Modern Drug Application
关键词
晚期
复发
卵巢癌
卡培他滨
Advanced
Recurrent
Ovarian cancer
Capecitabine
